Fig 5. TPP1 activity in Tpp1-/- transgenic mice containing TgUBC-cre/ERT2 after tamoxifen-induced cre-recombination.
TPP1 activity in Tpp1-/- transgenic mice containing TgUBC-cre/ERT2 without tamoxifen treatment was compared with other cohorts by one way ANOVA with Tukey’s multiple comparisons test. In brain, there was no significant difference in TPP1 activity between Tpp1-/- animals with or without treatment, and no significant difference between Tpp1f/f and tamoxifen-treated Tpp1-/- animals with TgUBC-cre/ERT2. All other comparisons were significant with p values ranging from <0.0001 to 0.0088. β-Galactosidase activity was significantly lower in Tpp1f/f animals compared to Tpp1-/- animals with or without treatment and untreated Tpp1-/- animals with TgUBC-cre/ERT2 (p values ranging from 0.0065 to 0.0449) while there was no significant difference between other comparisons. In liver, there was no significant difference in TPP1 activity between untreated Tpp1-/- animals, treated Tpp1-/- animals and untreated Tpp1-/- animals with TgUBC-cre/ERT2. All other comparisons were significant with p values ranging from <0.0001 to 0.0021. β-Galactosidase activity was significantly lower in Tpp1f/f animals compared to Tpp1-/- animals without treatment and tamoxifen-treated Tpp1-/- animals with TgUBC-cre/ERT2 (p values ranging from 0.0016 to 0.0125) while there was no significant difference between other comparisons.